Therapeutic potential (1)

1 Ferbas J Wallace D Weissman M . A systematic analysis of circulating B cell subsets in healthy subjects and in persons with SLE. Ann Rheum Dis 2006; 65: 584 [Abstract SAT0443].

2 Chambers S Rahman A Isenberg DA . Development of autoimmune disease in a multi-ethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Ann Rheum Dis 2007; 66: 1123 – 1127 .

3 Leandro MJ Cambridge G Edwards JC Ehrenstein MR Isenberg DA . B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005; 44: 1542 – 1545 .

4 Looney RJ Anolik JH Campbell D . B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 580 – 589 .

5 Sfikakis PP Boletis JN Lionaki S . Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 501 – 513 .

6 Ng K Leandro MJ Edwards JC Ehrenstein MR Cambridge G Isenberg DA . Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 942 – 945 .

7 Cambridge G Leandro M Teodoreseu M . B cell depletion in systemic lupus erythematosus: effect on autoantibody and anti-microbial antibody profiles. Arthritis Rheum 2006; 54: 3612 – 3622 .

8 Ng K Cambridge G Leandro MJ Edwards JCW Ehrenstein MR Isenberg DA . B cell depletion therapy in systemic lupus erythematosus: long term follow up and predictors of response. Ann Rheum Dis 2007; 66: 1259 – 1262 .